Diagnostichno-Konsultativen Tsentar XVIII-Sofia OOD
- Address
- lock Available on a paid plan
Diagnostichno-Konsultativen Tsentar XVIII-Sofia OOD
Diagnostichno-Konsultativen Tsentar XVIII-Sofia OOD is a clinical research facility in Sofia, Bulgaria, specializing in metabolic health and weight management studies. The center focuses on investigating novel therapeutic interventions for patients struggling with excess body weight and associated metabolic conditions.
- Weight management and obesity treatment research
- Metabolic disorder interventions
- Lifestyle modification programs combined with pharmacotherapy
The center conducts comprehensive investigations into body weight reduction therapies, evaluating innovative treatments as adjuncts to reduced-calorie diet and increased physical activity programs. Their research contributes to advancing evidence-based approaches for managing overweight and obesity, helping to develop more effective strategies for patients seeking sustainable weight loss solutions.
Site Overview
Activity Indicator
Last 6 months
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostichno-Konsultativen Tsentar XVIII-Sofia OOD
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Cagrilintide and Semaglutide in Combination for Weight Reduction in Patients with Overweight or Obesity | Novo Nordisk A/S | Phase III | Not Recruiting | Oct 2022 | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.